Article I: Noncompartmental methods of drug characterization: Statistical moment theory

Journal of the American Veterinary Medical Association

Volumn 213, Issue 7, 1998, Pages 974-980

  Martinez, Marilyn N ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VETERINARY DRUG;

ABSORPTION; ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DOSE RESPONSE; DRUG LABELING; LEGAL ASPECT; MICROBIOLOGICAL EXAMINATION; STATISTICAL MODEL; STATISTICS; SYSTEMS THEORY; UNITED STATES;

ABSORPTION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; STATISTICS; STOCHASTIC PROCESSES; SYSTEMS THEORY; UNITED STATES; VETERINARY DRUGS;

EID: 0032185402     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Martinez MN, Riviere JE, Koritz GD. Review of the first interactive workshop on professional flexible labeling. J Am Vet Med Assoc 1995;207:865-913.
2. Martinez MN, Brown SA, Copeland DD, et al. Professional flexible labeling workshop 11 task force report: developing a model of a professional veterinary drug label. J Am Vet Med Assoc 1996;209: 83-91.
3. Martinez MN, Brown SA, Copeland DD, et al. Professional flexible labeling workshop II task force report II: response to comments on their proposed model of a professional drug label. J Am Vet Med Assoc 1996;209:2068-2070.
4. Riviere JE. An AAVPT perspective: Pan II. In: Review of the first interactive workshop on professional flexible labeling. J Am Vet Med Assoc 1995;207:876-878.
5. Ritschel WA, Hammer GV. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. Int J Clin Pharmacol Ther Toxicol 1980;18:298-316.
6. Lees P, May SA, White D. Pharmacokinetics and dosage regimens of anti-inflammatory drugs. Ann Rech Vet 1990;21(Suppl1): 73-78.
7. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharm Biopharm 1978;6:547-557.
8. Riviere JE. Basic principles and techniques of pharmacokinetic modeling. J Zoo Wildl Med 1997;28:3-19.
9. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, lagrange, and spline approximation. J Pharm Biopharm 1978;6:79-98.
10. Chow WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharm Biopharm 1978;6:539-546.
11. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc, 1982.
12. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1995.
13. Martinez MN, Jackson AJ. Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUCO-INF). Pharm Res 1991;8:512-517.
14. Lovering EG, McGilveray IJ, McMillan I, et al. Comparative bioavailability from truncated blood level curves. J Pharm Sci 1975; 64:1521-1524.
15. Bois FY, Tozer TN, Hauck WW, et al. Bioequivalence: performance of several measures of extent of absorption. Pharm Res 1994;11:715-722.
16. Hennessy DR, Steel JW, Prichard RK. Biliary secretion and enterohepatic recycling of fenbendazole metabolites in sheep. J Vet Pharmacol Ther 1993;16:132-140.
17. Shepard TA, Gannaway DJ, Lockwood GF. Accumulation and time to steady-state for drugs subject to enterohepatic cycling: a simulation study. J Pharm Sci 1985;74:1331-1333.
18. Riviere JE. Pharmacologic principles of residue avoidance for veterinary practitioners. J Am Vet Med Assoc 1991;198:809-819.
19. Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991;20:429-446.
20. Perrier D, Ashley JJ, Levy G. Effect of product inhibition of kinetics of drug elimination. J Pharm Biopharm 1973;1:231-242.
21. Martinez MN, Berson MR. Bioavailability/bioequivalence assessments. In: Hardy G, Baggot JD, eds. The development of veterinary dosage forms. New York: Marcel Dekker Inc. 1998;429-467.
22. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharm Biopharm 1977;5:291-334.
23. Welling PG. Effect of food on bioavailability of drugs. Pharm Int 1980;1:14-18.
24. Walter-Sack I. The influence of nutrition on the systemic availability of drugs. Part II: drug metabolism and renal excretion. Klin Wochenschr 1987;65:1062-1072.
25. Koch PA, Schultz CA, Wills RJ, et al. Influence of food and fluid ingestion on aspirin bioavailability. J Pharm Sci 1978;67:1533-1535.
26. Martinez MN, Pelsor FR, Shaw VP, et al. Effect of dietary fat content on the bioavailability of sustained release quinidine gluconate tablet. Biopharm Drug Disp 1987;11:17-29.
27. Watson ADJ, Rjjnberk A. Systemic availability of o,p'-DDD in normal dogs, fasted and fed, and in dogs with hyperadrenocorticism. Res Vet Sci 1987;43:160-165.
28. Watson ADJ. Effect of ingesta on systemic availability of chloramphenicol from two oral preparations in cats. J Vet Pharmacol Ther 1979;2:117-121.
29. Watson AD, Emslie DR, Matin ICA, et al. Effect of ingesta on systemic availability of penicillins administered orally in dogs. J Vet Pharmacol Ther 1986;9:140-149.
30. Oukessou M, Toutain PL. Effect of dietary nitrogen intake on gentamicin disposition in sheep. J Vet Pharmacol Ther 1992;15: 416-420.
31. Taylor SM, Mallon TR, Blanchflower WJ, et al. Effects of diet on plasma concentrations of oral anthelmintics for cattle. Vet Rec 1992;130:264-268.
32. Sanchez SF, Alvarez LI, Lanusse CE. Nutritional condition affects the disposition of kinetics of albendazole in cattle. Xenobiotica 1996;26:307-320.
33. Ali DN, Hennessy DR. The effect of level of feed intake on the pharmacokinetic disposition and efficacy of ivermectin in sheep. J Vet Pharmacol Ther 1996;19:89-94.
34. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 3:413-420.
35. Shah VP, Lesko LJ, Fan J, et al. FDA guidance: dissolution testing of immediate release solid oral dosage forms. Rockville, Md: Center For Drug Evaluation and Research, Mar 14, 1995.
36. Malinowski H, Marroum P, Uppoor VR, et al. Guidance for industry: extended release solid oral dosage forms; development, evaluation and application of in-vitro/in-vivo correlations. Rockville, Md: Center For Drug Evaluation and Research, July 1, 1996 (not for implementation).
37. Kaartinen M, Salonen M, Alli L, et al. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J Vet Pharmacol Ther 1995;18: 357-362.
38. Reeves JS. Extra-vascular injections of antibiotics. J Antimicrob Chemother 1975;1:350-353.
39. Marshall AB, Palmer GH. Injection sites and drug bioavailability. Trends Vet Pharmacol Ther 1980;6:54-60.
40. Nouws JF, Vree TB. Effect of injection site on the bioavailability of an oxytetracycline formulation in ruminant calves. Vet Q 1983;5:165-170.
41. MacDiarmid SC. The absorption of drugs from subcutaneous and intramuscular injection sites. Vet Bull 1983;53:9-23.
42. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharm Biopharm 1980;8:509-534.
43. Benet LZ. Mean residence time in the body versus mean residence time in the central compartment. J Pharm Biopharm 1985;13: 555-558.
44. Brogan WL. Modern control theory. 3rd ed. Englewood Cliffs, NJ: Prentice-Hall Inc, 1991.
45. Macheras P, Argyrakis P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm Res 1997;14:842-847.